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Editorial on the Research Topic
Artemisinin—From Traditional Chinese Medicine to Artemisinin Combination Therapies;
Four Decades of Research on the Biochemistry, Physiology, and Breeding of Artemisia annua
The 2015 Nobel Prize in Physiology or Medicine was awarded to Tu Youyou for her “discoveries
concerning a novel therapy against malaria”. Educated in pharmaceutical sciences, Tu was recruited
to Chinese military research Program 523, with the aim of finding new drugs for the treatment of
malaria. A malaria epidemic during the Vietnam War had led Ho Chı ́Minh, the Prime Minister of
North Vietnam, to request medical help from China. In response, Chairman Mao approved Project
523, which involved over 500 scientists, military personnel, and medical practitioners and ran from
1967 to 1980. Whilst reviewing written records of traditional Chinese medicine, Tu noticed a
mention of Qinghao (Artemisia annua) for alleviation of malaria fevers in Ge Hong’s “A handbook
of prescriptions for emergencies”, which has been dated to around 317–420 A.D. She next found
that an ethyl ether extract from A. annua leaves strongly inhibited malaria, leading Tu and two
other members of her team to test the Qinghao plant extract for safety and side-effects on
themselves. In 1972, Tu´s team obtained the pure active substance from this extract and
determined its chemical structure, naming it as qinghaosu, or artemisinin, as it became more
commonly known in the West. A series of chemical derivatives of artemisinin were subsequently
developed by Project 523, including dihydroartemisinin, artemether, and artesunate. These
compounds have become part of the artemisinin combination therapies (ACTs), currently the
World Health Organisation (WHO)-recommended first-line drugs to combat malaria.
Almost fifty years after Tu´s discovery, malaria still poses a global threat, with an estimated 228
million cases occurring worldwide in 2018 causing 405,000 deaths – two thirds of them among
children under 5 years old in sub-Saharan Africa (World malaria report, 2019). The introduction of
ACTs (it is estimated that 3 billion treatment courses have been procured worldwide between 2010
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and 2018), rapid diagnostic tests (RDTs) and malaria vector
controls, including insecticide-treated mosquito nets, reduced
the number of cases significantly over the past 10 years (World
malaria report, 2019). However, artemisinin resistance conferred
by genetic mutations in Plasmodium falciparum recently
emerged in the Greater Mekong sub-region (Ariey et al., 2014)
together with Pfhrp2/3 gene deletions that render parasites
undetectable by RDT (Owusu et al., 2018), represent major
new threats in the global fight against malaria.
A. annua remains the sole global source of the drug at the
time of writing, despite significant efforts to develop alternative
production platforms, as discussed herein. National malaria
programmes delivered 214 million ACT treatment courses in
2018 (WHO Malaria report, 2019), equating to around 100
metric tonnes of pure artemisinin obtained from A. annua
(assuming 0.5 g artemisinin per treatment). The plant-sourced
drug demand stimulated breeding efforts to improve yields.
Widely practiced phenotypic selection of open pollination
varieties has been supplemented by modern molecular
breeding approaches, resulting in A. annua F1 hybrids that
yield almost 55 kg of artemisinin per hectare with a content
reaching 1.44% of leaf dry weight (Artemisia F1 Seed). Several
publications herein suggest that natural variation within A.
annua populations may have even more to offer in terms of
further improving yields. Wetzstein et al. show that further yield
improvements can be achieved through the use of phenotypic-
based selection and clonally propagating high-yielding
genotypes. Work from Ferreira et al. shows the importance of
a thorough understanding of seasonal variation of artemisinin
content in the A. annua crop when planning harvest and
maximising artemisinin returns from plantations. That work
also highlights existing differences in response to photoperiod
among different chemotypes of A. annua. Czechowski et al. shed
new light on the molecular basis of the existence of high- and
low- artemisinin producing chemotypes, providing candidate
targets for yield improvement through molecular breeding.
Transgenic routes, also being explored for further artemisinin
yield improvement in A. annua, have resulted in the elucidation of
much of the artemisinin biosynthetic pathway and the identification
of multiple transcriptional regulators of biosynthetic genes, as
reviewed by Ikram and Simonsen The same work also reviews
transgenic approaches that have succeeded in achieving an
artemisinin content of 2.6% leaf dry weight by overexpressing
biosynthetic genes; and over 3%, when metabolic pathways
competing for the five-carbon isoprenoid precursors are blocked.
Ma et al. and Tang et al. report on further transgenic approaches
that identify additional genes involved in the regulation of
artemisinin biosynthesis in A. annua. Fu et al. present work
adding to the sparse knowledge of the transport systems
potentially involved in regulation of artemisinin biosynthesis,
which may prove to be a valuable alternate route for genetic
improvement of artemisinin production. A number of the
transgenic approaches to improve artemisinin yield appear to
come at the cost of plant biomass and fitness, highlighting the
need for extensive field trials to validate laboratory and glasshouse
data. Regulatory approval will be required before release of these
GMOs, which remains a challenge for this high-profile medicinal
plant. Transgenics is, of course, also an extremely valuable
experimental tool for characterisation of in planta gene function,
yielding knowledge that is useful for both genome editing and
molecular breeding. In this context, Zhang et al. report on the
characterisation of genes involved in the supply of isoprene
precursors from the MEP-pathway and Catania et al. report on
the effects of silencing the first committed step in artemisinin
biosynthesis using an RNAi approach. This latter study also
opens up the prospect of using A. annua as a production
platform for other high value sesquiterpenes.
Attempts to transfer artemisinin production to other plant and
microbial hosts are reviewed by Ikram and Simonsen and Kung
et al. Achievements of the Keasling group in engineering
Saccharomyces cerevisiae that produces the artemisinin precursor,
artemisinic acid, at yields of 25 g/L remains an exemplar for
successful metabolic engineering (Paddon et al., 2013). However,
costs associated with the non-enzymatic photochemical conversion
of artemisinic acid to artemisinin have proved too expensive to
allow the semi-synthetic route to compete with plant-based
production, where both enzymatic and non-enzymatic steps are
conducted in glandular secretory trichomes, which are specialized
10-cell structures found on the surface of the leaf, stems and flower
buds (Peplow, 2016). Kung et al. discuss recent developments in the
chemical conversions of artemisinic acid to artemisinin potentially
replacing costly photochemical processes developed by Sanofi,
raising the prospect once again of an alternative source of
artemisinin that would help stabilise supply.
Ikram and Simonsen review the prospect of engineering plant
heterologous systems for artemisinin production and report a
proof-of-concept in Nicotiana species, albeit at yields significantly
less than for A. annua itself. The presence of endogenous
glycosyltransferases in Nicotiana species that are able to
glycosylate the engineered artemisinin precursors, rendering them
unsuitable for further spontaneous conversions into artemisinin,
makes the use of these species as production hosts particularly
challenging. In an effort to find an alternative host with less
glycosyltransferase activity, Ikram et al. have evaluated the non-
vascular plant, Physcomitrella patens. The artemisinin levels
achieved in this moss species were significantly higher than those
from Nicotania species, but still around 100-times lower than those
found in A. annua.
The use of monotherapies that rely on artemisinin or its
derivatives as the sole antimalarial agents is not recommended by
the World Health Organisation since this practice significantly
increases the risk of the emergence of parasite resistance. Some
previous literature has supported the use ofA. annua herbal remedies
as cost-effective alternatives to ACTs with the suggestion that
artemisinin works in combination with other compounds, such as
flavonoids (for exampleWeathers et al., 2014). Czechowski et al. used
in vitro assays with whole plant extracts from a series of A. annua
mutants, deficient in either the production of artemisinin or
flavonoids, to demonstrate that artemisinin is the sole metabolite
from A. annua with in vitro anti-plasmodial activity. The possibility
of other compounds having in vivo effects was also discussed as it is
recognised that in vitro and in vivo studies do not always recapitulate
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one another in therapeutics development. This study has recently
been cited as evidence in a WHO position paper that does not
support the promotion or use of Artemisia plantmaterial in any form
for the prevention or treatment of malaria (WHO, 2019).
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